Learning lessons from drugs that have recently entered the market

Drug Discovery Today

Volumn 16, Issue 9-10, 2011, Pages 398-411

  Teague, Simon J ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE BROMIDE; ALVIMOPAN; BLONANSERIN; CEFTOBIPROLE MEDOCARIL; CERTOLIZUMAB PEGOL; CHOLINE FENOFIBRATE; CILASTATIN; CIPROFIBRATE; CLEVIDIPINE; DABIGATRAN ETEXILATE; DESVENLAFAXINE; ENOXAPARIN; ETRAVIRINE; FENOFIBRATE; FESOTERODINE; HALOPERIDOL; HARKOSERIDE; ICATIBANT; IMIPENEM; PIRFENIDONE; PLACEBO; RILONACEPT; RIVAROXABAN; SITAFLOXACIN; SUGAMMADEX; TAFLUPROST; TIMOLOL; UMIROLIMUS; UNINDEXED DRUG; VANCOMYCIN;

CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG CONTROL; DRUG FORMULATION; DRUG INDUSTRY; DRUG INFORMATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; HUMAN; NONHUMAN; PHARMACODYNAMICS; POLICY; PRODUCTIVITY; REVIEW; STUDY DESIGN; TOXICOLOGICAL PARAMETERS;

ANIMALS; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 79956024496     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.03.003     Document Type: Review

References (47)

1. S. Hedge, and M. Schmidt To market, to market - 2008 Annu. Rep. Med. Chem. 44 2009 577 632
2. J. Mitri, and A.G. Pittas Inhaled insulin - what went wrong? Nat. Rev. Endocrinol. 5 2009 24 25
3. M. Allison PML problems loom for rituxan Nat. Biotechnol. 28 2010 105 106
4. M. Wehling Assessing the translatability of drug projects: what needs to be scored to predict success? Nat. Rev. Drug Discov. 8 2009 541 546
5. UPS The USP Dictionary of USAN and International Drug Names 2010 US Pharmacopeial Convention
6. B. Booth, and R. Zemmel Prospects for productivity Nat. Rev. Drug Discov. 5 2004 451 456 (Pubitemid 38618127)
7. S. Lewis, and J. Liberman CATIE and CUtLASS: can we handle the truth? Br. J. Psychiatry 192 2008 161 163 (Pubitemid 351347371)
8. J.M. Mallion, and J.P.J. Baguet Putting the efficacy of candestan cilexetil into perspective: a review of new comparative data Human Hypertens. Suppl. 2 2000 S33 S41
9. A.M. Bal The echinocandins: three useful choices or three too many? Int. J. Antimicrob. Agents 35 2010 13 18
10. P. Nightingale, and P. Martin The myth of the biotech revolution Trends Biotechnol. 22 2004 564 569 (Pubitemid 39371137)
11. S.D. Roger Biosimilars: current status and future directions Expert Opin. Biol. Ther. 10 2010 1011 1018
12. H. Yang, and D.M. Rotstein Novel CCR5 antagonists for the treatment of HIV infection: a review of compounds patented in 2006-2008 Expert Opin. Ther. Patents 20 2009 325 354
13. Biggadike, K. et al. (2002) A novel androstane as an anti-inflammatory agent. GlaxoSmithKleine, WO2002012265A1
14. Gore, P.M. et al. (2009) Preparation of quinolinyloxypiperidine and pyrrolidine derivatives for the treatment of inflammatory and allergic diseases of the respiratory tract. GlaxoSmithKleine, WO2009021965A2
15. Guile, S. et al. (2000) Novel triazolo[4,5-d]pyrimidine compounds. AstraZeneca, WO2000034283A1
16. H. Klitgaard Antiepileptic drug discovery: lessons from the past and future challenges Acta Neurol. Scand. 112 Suppl. 181 2005 68 72
17. P. Kwan The mechanism of action of commonly used antiepileptic drugs Pharmacol. Therap. 90 2001 21 34 (Pubitemid 32622838)
18. M.A. Lindsay Finding new drug targets in the 21st century Drug Discov. Today 10 2005 1683 1687 (Pubitemid 41817617)
19. S.J. Enna, and M. Williams Defining the role of pharmacology in the emerging world of translational research Adv. Pharmacol. 57 2009 1 30
20. U. Meyer From khellin to sodium cromoglycate - a tribute to the work of Dr. R.E.C. Altounyan (1922-1987) Pharmazie 57 2002 62 69 (Pubitemid 34101784)
21. Wiechert, R. and Schering, A.G. (2006). The history of drospirenone. Berlin, Germany. Fischer, Janos; Ganellin, C. Robin (Editors). Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, Analogue-Based Drug Discovery 395-400.
22. P.M. LoRusso Phase 0 clinical trials: an answer to drug development stagnation? J. Clin. Oncol. 27 2009 2586 2588
23. D.S. Shewach Metabolism and selective cytotoxicity of 9-beta-d-arabinofuranosylguanine in human lymphoblasts Cancer Res. 45 1985 1008 1014 (Pubitemid 15111252)
24. P. Lindberg Omeprazole: the first proton pump inhibitor Med. Res Rev. 10 1990 1 54 (Pubitemid 20018270)
25. J.F. Ryley The node of action of proguanil and related antimalarial drugs Br. J. Pharmacol. 8 1953 424 430
26. G.B. Elion Metabolic studies of allopurinol, an inhibitor of xanthine oxidase Biochem. Pharmacol. 15 1966 863 889
27. R.E. Haddock Metabolism of nabumetone (BRL 14777) by various species including man Xenobiotica 14 1984 327 337 (Pubitemid 14108125)
28. M.J. Brodie, and M.A. Dichter Antiepileptic drugs N. Engl. J. Med. 334 1996 168 173
29. T. Gordi, and E.-I. Lepist Artemisinin derivatives: toxic for laboratory animals, safe for humans? Response to comments Toxicol. Lett. 151 2004 491 492
30. T. Efferth, and B. Kaina Toxicity of the antimalarial artemisinin and its derivatives Crit. Rev. Toxicol. 40 2010 405 421
31. K.T. Fitzgerald 'Over the counter' drug toxicity in companion animals Clin. Technol. Small Anim. Pract. 21 2006 215 226 (Pubitemid 44909547)
32. G. De Stevens My odyssey in drug discovery J. Med. Chem. 34 1991 2665 2670
33. M.C. Wenlock A comparison of physiochemical property profiles of development marketed oral drugs J. Med. Chem. 46 2003 1250 1256 (Pubitemid 36428230)
34. R.A. Copeland The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety Expert Opin. Drug Discov. 5 2010 305 310
35. D.J. Payne Drugs for bad bugs: confronting the challenges of antibacterial drug discovery Nat. Rev. Drug Discov. 6 2007 29 40 (Pubitemid 46020284)
36. H. Pearson One gene, twenty years Nature 460 2009 165 169
37. S.I. Rennard, and J.V. Vestbo The many 'small COPDs': COPD should be an orphan disease Chest 134 2008 623 627
38. J.U. Adams Building the bridge from bench to bedside Nat. Rev. Drug Discov. 7 2008 463 465
39. G.A. FitzGerald Moving clinical research in academic medical centers up the value chain Nat. Rev. Drug Discov. 8 2009 597
40. E.N. Bonabeau A more rational approach to new-product development Harvard Bus. Rev. 86 2008 96 102
41. P. Lindberg Omeprazole J.B. Taylor, D.J. Triggle, Comprehensive Medicinal Chemistry II vol. 8 2007 Elsevier 213 225
42. G. De Stevens Serendipity and structured research in drug discovery Progr. Drug Res. 30 1986 189 203 (Pubitemid 17002837)
43. P. Cuatrecasas Drug discovery in jeopardy J. Clin. Invest. 116 2006 2837 2842 (Pubitemid 44684465)
44. D. Erickson Wanted: drug hunters In Vivo 2003 45 52
45. A. Huxley, and N. Miles Speedel on the company's pipeline and future plans Drug Discov. Today 10 2005 881 883
46. H. Fleisch Prevention by a diphosphonate of immobilization 'osteoporosis' in rats Nature 223 1969 211 212
47. H. Stahelin Historical background (Ciclosporin) Progr. Allergy 38 1986 19 27